Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma

Owing to limited therapeutic regimens after the failure of first-line platinum-based chemotherapy in patients with refractory thymic epithelial tumors, alternative therapeutic strategies have been considered, including immune checkpoint inhibitors.1,2 Pembrolizumab is a humanized monoclonal antibody against programmed cell death-1 (PD-1),3 and 2 phase II clinical trials have recently shown therapeutic benefits of pembrolizumab for thymic...